Parasites are ubiquitous and have well-documented ecological consequences. In contrast, the extent to which parasites drive phenotypic evolution in hosts remains obscure. We use a recently developed statistical technique--selective source analysis--to analyse the strength of phenotypic selection acting on floral traits in the plant Heuchera grossulariifolia attributable to attack by the seed-parasitic moth, Greya politella. This analysis spanned 3 years and included two sympatric populations of the host plant H. grossulariifolia that differ in ploidy. Our analyses revealed that attack by G. politella contributed to phenotypic selection for flowering time and floral display size, favouring earlier flowering in the polyploid population, later flowering in the diploid population and increased floral display size in the polyploid population. Although selection imposed by parasite attack was generally quite weak, in one of the 3 years parasites generated a modestly strong selection gradient (beta = -0.059) that explained 38.6% of total observed phenotypic selection for earlier flowering in the polyploid population. Together, our results demonstrate parasites can generate significant phenotypic selection, but that such selection may be sporadic across populations and time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1420-9101.2008.01551.x | DOI Listing |
J Evol Biol
January 2025
Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals de la Universitat de Barcelona (BEECA), Institut de Recerca de la Biodiversitat (IRBio), Universitat de Barcelona.
Differences in habitat use impose ecological constraints which in turn lead to functional and morphological differences through adaptation. In fact, a convergent evolutionary pattern is evident when species exhibit similar responses to similar environments. In this study we examine how habitat use influences the evolution of body shape in lizards from the family Lacertidae.
View Article and Find Full Text PDFAlzheimers Dement (Amst)
January 2025
Introduction: Studies have shown that blood biomarkers can differentiate dementia disorders. However, the diagnosis of dementia still relies primarily on cerebrospinal fluid and imaging modalities. The new disease-modifying treatments call for more widely applicable biomarkers.
View Article and Find Full Text PDFGenet Med Open
October 2024
Department of Clinical and Biomedical Sciences, Medical School, University of Exeter, St Luke's Campus, Exeter, United Kingdom.
Purpose: We sought to evaluate outcomes for clinical management after a genetic diagnosis from the Deciphering Developmental Disorders study.
Methods: Individuals in the Deciphering Developmental Disorders study who had a pathogenic/likely pathogenic genotype in the DECIPHER database were selected for inclusion ( = 5010). Clinical notes from regional clinical genetics services notes were reviewed to assess predefined clinical outcomes relating to interventions, prenatal choices, and information provision.
Aging Cell
January 2025
Chemical and Biological Integrative Research Center, Biomedical Research Division, Korea Institute of Science and Technology, Seoul, Republic of Korea.
As emerging therapeutic strategies for aging and age-associated diseases, various biochemical approaches have been developed to selectively remove senescent cells, but how physical stimulus influences senescent cells and its possible application in senolytic therapy has not been reported yet. Here we developed a physical method to selectively stimulate senescent cells via low-intensity pulsed ultrasound (LIPUS) treatment. LIPUS stimulation did not affect the cell cycle, but selectively enhanced secretion of specific cytokines in senescent cells, known as the senescence-associated secretory phenotype (SASP), resulting in enhanced migration of monocytes/macrophages and upregulation of phagocytosis of senescent cells by M1 macrophage.
View Article and Find Full Text PDFOncol Ther
January 2025
Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I-Sapienza University, Via Benevento 6, 00161, Rome, Italy.
Introduction: Myelofibrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fibrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the first-in-class janus kinase 2 (JAK2) inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. The red cell distribution width (RDW) is the measure of erythrocyte volume variability (anisocytosis).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!